{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:29:31Z","timestamp":1757456971114,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12325-022-02114-4","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T22:03:52Z","timestamp":1648159432000},"page":"2489-2501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine"],"prefix":"10.1007","volume":"39","author":[{"given":"A. Elif","family":"M\u00fcderrisoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Oelke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Murgas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean J. M. C. H.","family":"de la Rosette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-8467","authenticated-orcid":false,"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"issue":"3","key":"2114_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/ju.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J Urol. 2019;202(3):558\u201363. https:\/\/doi.org\/10.1097\/ju.0000000000000309.","journal-title":"J Urol"},{"issue":"6","key":"2114_CR2","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","volume":"62","author":"MG Lucas","year":"2012","unstructured":"Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012;62(6):1130\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2012.08.047.","journal-title":"Eur Urol"},{"issue":"11","key":"2114_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021889","volume":"8","author":"G Yeowell","year":"2018","unstructured":"Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11): e021889. https:\/\/doi.org\/10.1136\/bmjopen-2018-021889.","journal-title":"BMJ Open"},{"issue":"4","key":"2114_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.juro.2013.10.046","volume":"191","author":"PW Veenboer","year":"2014","unstructured":"Veenboer PW, Bosch JLHR. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003\u20138. https:\/\/doi.org\/10.1016\/j.juro.2013.10.046.","journal-title":"J Urol"},{"key":"2114_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4111\/icu.2016.57.2.84","volume":"57","author":"TH Kim","year":"2016","unstructured":"Kim TH, Lee KS. Persistence and compliance with medication management in the treatment of overactive bladder. Investig Clin Urol. 2016;57:84\u201393. https:\/\/doi.org\/10.4111\/icu.2016.57.2.84.","journal-title":"Investig Clin Urol"},{"issue":"9","key":"2114_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"JS Benner","year":"2010","unstructured":"Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276\u201382. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.09036.x.","journal-title":"BJU Int"},{"issue":"10","key":"2114_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00192-015-2674-0","volume":"26","author":"U Schwantes","year":"2015","unstructured":"Schwantes U, Grosse J, Wiedemann A. Refractory overactive bladder: a common problem? Int Urogynecol J. 2015;26(10):1407\u201314. https:\/\/doi.org\/10.1007\/s00192-015-2674-0.","journal-title":"Int Urogynecol J"},{"issue":"5","key":"2114_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/bju.13945","volume":"120","author":"MJ Drake","year":"2017","unstructured":"Drake MJ, Nitti VW, Ginsberg DA, et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017;120(5):611\u201322. https:\/\/doi.org\/10.1111\/bju.13945.","journal-title":"BJU Int"},{"issue":"1","key":"2114_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","volume":"70","author":"MJ Drake","year":"2016","unstructured":"Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegon add-on therapy to solifenacin in incontinent overactive bladder patients with an iInadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136\u201345. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.030.","journal-title":"Eur Urol"},{"issue":"6","key":"2114_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/nau.24706","volume":"40","author":"AS Wagg","year":"2021","unstructured":"Wagg AS, Herschorn S, Carlsson M, Fernet M, Oelke M. What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine. Neurourol Urodyn. 2021;40(6):1559\u20131568. https:\/\/doi.org\/10.1002\/nau.24706.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"2114_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000096338","volume":"77","author":"KP J\u00fcnemann","year":"2006","unstructured":"J\u00fcnemann KP, Hessd\u00f6rfer E, Unamba-Oparah I, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006;77(4):334\u20139. https:\/\/doi.org\/10.1159\/000096338.","journal-title":"Urol Int"},{"key":"2114_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1159\/000020221","volume":"37","author":"W Dorschner","year":"2000","unstructured":"Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol. 2000;37:702\u20138.","journal-title":"Eur Urol"},{"issue":"5","key":"2114_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bju.15020","volume":"125","author":"M Yoshida","year":"2020","unstructured":"Yoshida M, Takeda M, Gotoh M, et al. Efficacy of vibegron, a novel \u03b23-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020;125(5):709\u201317. https:\/\/doi.org\/10.1111\/bju.15020.","journal-title":"BJU Int"},{"key":"2114_CR14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306\u201315. https:\/\/doi.org\/10.1016\/j.eururo.2006.09.019.","journal-title":"Eur Urol"},{"issue":"3","key":"2114_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1464-410X.2007.07031.x","volume":"100","author":"O Yamaguchi","year":"2007","unstructured":"Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100(3):579\u201387. https:\/\/doi.org\/10.1111\/j.1464-410X.2007.07031.x.","journal-title":"BJU Int"},{"issue":"1","key":"2114_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.eururo.2009.04.045","volume":"57","author":"F Zatura","year":"2010","unstructured":"Zatura F, Vsetica J, Abdias M, et al. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol. 2010;57(1):145\u201352.","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"2114_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000052400","volume":"38","author":"MC Michel","year":"2000","unstructured":"Michel MC, Goepel M. Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice. Eur Urol. 2000;38(Suppl 1):40\u20137. https:\/\/doi.org\/10.1159\/000052400.","journal-title":"Eur Urol"},{"key":"2114_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3389\/fphar.2020.00816","volume":"11","author":"MC Michel","year":"2020","unstructured":"Michel MC, Schumacher H, Mehlburger L, de la Rosette JJMCH. Factors associated with nocturia-related quality of life in men with lower urinary tract symptoms and treated with tamsulosin oral controlled absorption system in a noniInterventional study. Front Pharmacol. 2020;11:816. https:\/\/doi.org\/10.3389\/fphar.2020.00816.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2114_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/01.ju.0000103540.71683.e5","volume":"171","author":"JR Landis","year":"2004","unstructured":"Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol. 2004;171(2):752\u20136.","journal-title":"J Urol"},{"issue":"3","key":"2114_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/01.ju.000027180.43797.0e","volume":"168","author":"MC Michel","year":"2002","unstructured":"Michel MC, Schneider T, Krege S, Goepel M. Do gender or age affect the efficacy and safety of tolterodine? J Urol. 2002;168(3):1027\u201331. https:\/\/doi.org\/10.1097\/01.ju.000027180.43797.0e.","journal-title":"J Urol"},{"key":"2114_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/jcm10020311","volume":"10","author":"M Amiri","year":"2021","unstructured":"Amiri M, Schneider T, Oelke M, Murgas S, Michel MC. Factors associated with decisions for initial dosing, up-titration of propiverine and treatment outcomes in overactive bladder syndrome patients in a non-interventional setting. J Clin Med. 2021;10:311. https:\/\/doi.org\/10.3390\/jcm10020311.","journal-title":"J Clin Med"},{"issue":"2","key":"2114_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/nau.24275","volume":"39","author":"M Amiri","year":"2020","unstructured":"Amiri M, Murgas S, Stang A, Michel MC. Do overactive bladder symptoms and their treatment-associated changes exhibit a normal distribution? Implications for analysis and reporting. Neurourol Urodyn. 2020;39(2):754\u201361. https:\/\/doi.org\/10.1002\/nau.24275.","journal-title":"Neurourol Urodyn"},{"unstructured":"Dimpfl T, K\u00f6lbl H, Peschers U, et al. The overactive bladder. AWMF: Frankfurt; 2010; https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/015-007l_S2k_Ueberaktive_Blase_2010-abgelaufen.pdf. Accessed 10 Mar 2022.","key":"2114_CR23"},{"issue":"7748","key":"2114_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","volume":"567","author":"V Amrhein","year":"2019","unstructured":"Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305\u20137. https:\/\/doi.org\/10.1038\/d41586-019-00857-9.","journal-title":"Nature"},{"issue":"1","key":"2114_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/mol.119.118927","volume":"97","author":"MC Michel","year":"2020","unstructured":"Michel MC, Murphy TJ, Motulsky HJ. New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology. Mol Pharmacol. 2020;97(1):49\u201360. https:\/\/doi.org\/10.1124\/mol.119.118927.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2114_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2011.05.065","volume":"61","author":"V Kupelian","year":"2012","unstructured":"Kupelian V, Wei JT, O\u2019Leary MP, Norgaard JP, Rosen RC, McKinlay JB. Nocturia and quality of life: results from the Boston area community health survey. Eur Urol. 2012;61(1):78\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.065.","journal-title":"Eur Urol"},{"issue":"5","key":"2114_CR27","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00345-014-1374-6","volume":"32","author":"M Oelke","year":"2014","unstructured":"Oelke M, Wiese B, Berges R. Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older. World J Urol. 2014;32(5):1155\u201362. https:\/\/doi.org\/10.1007\/s00345-014-1374-6.","journal-title":"World J Urol"},{"issue":"3","key":"2114_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.eururo.2009.03.080","volume":"57","author":"KAO Tikkinen","year":"2010","unstructured":"Tikkinen KAO, Johnson TM II, Tammela TLJ, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol. 2010;57(3):488\u201398. https:\/\/doi.org\/10.1016\/j.eururo.2009.03.080.","journal-title":"Eur Urol"},{"key":"2114_CR29","first-page":"53","volume":"114","author":"G Larsson","year":"1988","unstructured":"Larsson G, Victor A. Micturition patterns in a healthy female population, studied with a frequency\/volume chart. Scand J Urol Nephrol Suppl. 1988;114:53\u20137.","journal-title":"Scand J Urol Nephrol Suppl"},{"issue":"1","key":"2114_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/nau.2093","volume":"21","author":"MP FitzGerald","year":"2002","unstructured":"FitzGerald MP, Butler N, Shott S, Brubaker L. Bother arising from urinary frequency in women. Neurourol Urodyn. 2002;21(1):36\u201340.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"2114_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3109\/00365599509180578","volume":"29","author":"D Mazur","year":"1995","unstructured":"Mazur D, Wehnert J, Dorschner W, Schubert G, Herfurth G, Alken RG. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. Scand J Urol Nephrol. 1995;29(3):289\u201394. https:\/\/doi.org\/10.3109\/00365599509180578.","journal-title":"Scand J Urol Nephrol"},{"issue":"6","key":"2114_CR32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/iju.12372","volume":"21","author":"O Yamaguchi","year":"2014","unstructured":"Yamaguchi O, Uchida E, Higo N, Minami H, Kobayashi S, Sato H. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized, double-blind trial. Int J Urol. 2014;21(6):586\u201393. https:\/\/doi.org\/10.1111\/iju.12372.","journal-title":"Int J Urol"},{"issue":"3","key":"2114_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.eururo.2005.04.023","volume":"48","author":"KP J\u00fcnemann","year":"2005","unstructured":"J\u00fcnemann KP, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol. 2005;48(3):478\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.023.","journal-title":"Eur Urol"},{"issue":"6","key":"2114_CR34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1464-410x.1999.00251.x","volume":"84","author":"H Madersbacher","year":"1999","unstructured":"Madersbacher H, Halaska M, Voigt R, Alloussi S, H\u00f6fner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999;84(6):646\u201351. https:\/\/doi.org\/10.1046\/j.1464-410x.1999.00251.x.","journal-title":"BJU Int"},{"issue":"6","key":"2114_CR35","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.juro.2012.11.178","volume":"181","author":"K Stav","year":"2009","unstructured":"Stav K, Dwyer PL, Rosamilia A. Women overestimate daytime urinary frequency: the importance of the bladder diary. J Urol. 2009;181(6):2176\u201380. https:\/\/doi.org\/10.1016\/j.juro.2012.11.178.","journal-title":"J Urol"},{"issue":"11","key":"2114_CR36","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s00120-009-2086-1","volume":"48","author":"PL Kessler-Zumpe","year":"2009","unstructured":"Kessler-Zumpe PL, Murgas S, Neumann G, Richter AE. Therapie der \u00fcberaktiven Blase mit Propiverin ER. Urologe. 2009;48(11):1346\u201351. https:\/\/doi.org\/10.1007\/s00120-009-2086-1.","journal-title":"Urologe"},{"issue":"2","key":"2114_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00345-011-0654-7","volume":"29","author":"M Oelke","year":"2011","unstructured":"Oelke M, Murgas S, Baumann I, Schnabel F, Michel MC. Efficacy of propiverine ER with or without \u03b1-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. World J Urol. 2011;29(2):217\u201323. https:\/\/doi.org\/10.1007\/s00345-011-0654-7.","journal-title":"World J Urol"},{"issue":"6","key":"2114_CR38","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/AOG.0000000000000851","volume":"125","author":"WS Reynolds","year":"2015","unstructured":"Reynolds WS, McPheeters M, Blume J, et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women. A systematic review and meta-analysis. Obstet Gynecol. 2015;125(6):1423\u201332. https:\/\/doi.org\/10.1097\/AOG.0000000000000851.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2114_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167\u201378. https:\/\/doi.org\/10.1002\/nau.10052.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"2114_CR40","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.eururo.2012.07.004","volume":"62","author":"JN Cornu","year":"2012","unstructured":"Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definitions, epidemiology, pathophysiology and management. A systematic review and meta-analysis. Eur Urol. 2012;62(5):877\u201390. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.004.","journal-title":"Eur Urol"},{"issue":"9","key":"2114_CR41","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1742-1241.2010.02442.x","volume":"64","author":"T Schneider","year":"2010","unstructured":"Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC. Do gender, age or life style factors affect responses to anti-muscarinic treatment in overactive bladder patients? Int J Clin Pract. 2010;64(9):1287\u201393. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02442.x.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"2114_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1757-5672.2009.00051.x","volume":"1","author":"LPW Witte","year":"2009","unstructured":"Witte LPW, Peschers U, Vogel M, de la Rosette JJMCH, Michel MC. Does the number of previous vaginal deliveries affect overactive bladder symptoms or their response to treatment? LUTS. 2009;1(2):82\u20137. https:\/\/doi.org\/10.1111\/j.1757-5672.2009.00051.x.","journal-title":"LUTS"},{"issue":"2","key":"2114_CR43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","volume":"63","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and effiaccy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296\u2013305. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.048.","journal-title":"Eur Urol"},{"issue":"1","key":"2114_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eururo.2004.11.012","volume":"48","author":"MC Michel","year":"2005","unstructured":"Michel MC, de la Rosette JJMCH, Piro M, Schneider T. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol. 2005;48(1):110\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2004.11.012.","journal-title":"Eur Urol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02114-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:34:38Z","timestamp":1653042878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02114-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2114"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02114-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}